HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulseâ"¢ technology using its proprietary Nanosecond Pulsed Field Ablationâ"¢ (nanosecond PFA or nsPFAâ"¢) energy, today announced the enrollment of the first patient in its NANOCLAMP AF Study for the treatment of atrial fibrillation (AF). The successful first procedure was completed at St. Helena Hospital in St. Helena, California, with the nPulseâ"¢ Cardiac Surgical System following its recent FD. ...

公司临床研究进展 - 公司公布其nPulse心脏外科系统的首次人体可行性研究的最新临床研究结果 [1] - 研究结果在丹麦哥本哈根举行的第39届欧洲心胸外科协会年会上作为最新突破性进展发布 [1] 公司技术平台 - 公司核心技术为新颖的nPulse技术平台 [1] - 该技术平台利用其专有的纳秒脉冲场消融能量 [1]